Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3999649 | Urologic Oncology: Seminars and Original Investigations | 2015 | 7 Pages |
Abstract
In the United States, nearly half of men with low-risk prostate cancer experience at least one adverse pathologic outcome at RP. Delaying RP up to 12 months did not change the risk of adverse pathology. Men may safely use the time following their initial biopsy to consider management options and obtain a restaging biopsy, if recommended.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Adam B. B.S., Sanjay G. M.D., Scott E. M.D.,